ExxonMobil reports first-quarter results on May 1 with short sellers materially pulling back even as the stock absorbs a steep one-month decline.
The clearest positioning signal is the retreat in short interest. SI has fallen roughly 17% over the past month to just 1.0% of the free float — and dropped another 7.4% in a single session on April 24. Borrow costs are near the floor at 0.39% APR, and utilization has collapsed from a 52-week high of 2.14% in mid-March to just 0.46% today. That is not the footprint of bears pressing a thesis. The lending market has gone from its most active of the past year to almost entirely dormant in six weeks. Options tell the same story: the put/call ratio at 0.62 is marginally below its 20-day average of 0.65 and well beneath the 52-week high of 0.90, suggesting options traders are not scrambling for downside protection heading into the print. Price action is the one complication — XOM has shed 13% over the past month to $148.19, though it steadied with a small gain on the week.
The debate heading in centres on whether the integrated model and cost discipline can offset macro headwinds. Bears point to weakness in oil prices and petrochemical margins, the risk of cost overruns on major capital projects, and a Q1 chemicals division that has already disappointed. The company's EV/EBITDA has compressed by roughly 1.2 turns over the past month, reflecting those concerns. Bulls counter with strong EPS momentum — ranking in the 78th percentile on 30-day forward EPS estimate momentum and the 80th on 90-day — alongside a dividend score in the 97th percentile and a diversified global portfolio that gives XOM structural resilience other E&P names lack. Analyst activity has been mixed but largely constructive: Morgan Stanley trimmed its target modestly to $171 while keeping Overweight, JPMorgan raised its target to $170 from $140, and most firms maintaining buy-equivalent ratings held their ground. Wolfe Research was the lone downgrade, moving to Peer Perform on April 21. The consensus mean target of $166 implies roughly 12% upside from current levels.
The institutional base remains anchored. Vanguard and BlackRock together hold over 17% of shares, and both added modestly in Q1. Recent insider activity has been limited to small, low-significance sales by a single vice president — nothing that changes the picture either way.
Across correlated peers, the week-on-week pattern is notably divergent. COP, APA, OXY, and DVN each gained 4-8% on the week, while XOM was essentially flat. That divergence underscores how closely the May 1 print will be read against the peer set.
Overall, positioning looks unambiguously relaxed rather than defensive: short sellers have retreated, borrow conditions are loose, and options hedging is below-average. The earnings report will therefore test whether XOM's integrated scale and capital discipline can justify the premium it has historically commanded — even as the macro backdrop for oil and chemicals remains uncertain.
See the live data behind this article on ORTEX.
Open XOM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
